M&A / Deals

Gilead Sciences completes Tubulis acquisition for $5bn

Pharmaceutical Technology

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.

Read full story

pharminent May 22, 2026 (Last updated: May 22, 2026)

Pharmaceutical Technology

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.

Read full story